# US 2021/0300871 A1 · Aryl-n-aryl derivatives for treating a rna virus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0300871 A1
- Document ID: US20210300871A1
- Status: Published application
- Kind: A1
- Application number: 17/259,483
- Filed: 2019-07-09
- Published: 2021-09-30
- Earliest claimed: 2018-07-09
- Assignees: Abivax; Centre National De La Recherche Scientifique; Universite De Montpellier; Institut Curie
- Applicants: Abivax; Centre National De La Recherche Scientifique; Universite De Montpellier; Institut Curie
- Inventors: Didier SCHERRER; Jamal TAZI; Florence MAHUTEAU-BETZER; Romain NAJMAN; Julien SANTO; Cécile APOLIT
- Web page: https://patentgrep.com/patent/US20210300871A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 31/12: Antivirals
- C07C 233/65: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 237/40: having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
- C07C 255/50: to carbon atoms of non-condensed six-membered aromatic rings
- C07C 311/16: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 213/38: having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 213/81: Amides; Imides
- C07D 239/12: Nitrogen atoms not forming part of a nitro radical
- C07D 239/16: acylated on said nitrogen atoms
- C07D 239/22: with hetero atoms directly attached to ring carbon atoms
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 241/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for treating and/or preventing a subject from a RNA virus infection caused by a virus belonging to group IV or V of the Baltimore classification comprising the administration to a patient in need thereof of a therapeutically effective quantity of a compound of formula (I):
wherein:
ring and
ring independently mean a phenylene or a pyridylene group,
X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group,
Y1 represents an aryl group selected from a pyridyl group, a pyrazinyl group or a pyrimidinyl group,
X2 represents
a —O— group,
a —CO—NH— group,
a —NH—CO—NH— group,
a —OCH2— group,
a —NH—CO— group,
a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms
or
a —SO2—NH— group,
n is 0, 1, 2 or 3,
m and m′ are independently 0, 1 or 2,
Y2 represents
a hydrogen atom,
a hydroxyl group,
a morpholinyl group,
a piperidinyl group, optionally substituted by a (C1-C4)alkyl group,
a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or
a —CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group, said (C3-C8)cycloalkyl group being optionally substituted by one or two (C1-C4)alkyl group, halogen atom or (C1-C4)alkoxy group and said (C3-C8)cycloalkyl group being optionally interrupted on said R1 and/or R2 by an oxygen atom,
or alternatively X2—Y2 represents a group —C(═O)—NRcRd, wherein Rc and Rd form, together with the nitrogen atom a saturated heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl derivative, or by a trifluoromethyl group,
R and R′ independently represent
a (C1-C4)alkyl group,
a (C3-C6)cycloalkyl group,
a halogen atom,
a (C1-C5)alkoxy group,
a —SO2—NRaRb group,
a —SO3H group,
a —OH group, or
a —O—SO2—ORc group,
provided that when X1 is a —NH—CO— group, Y1 may further be a phenyl group optionally substituted by one or two substituent(s) selected from a halogen atom, a (C1-C4)alkyl group, a cyano group, a (C1-C5)alkoxy group, a trifluoromethyl group, a trifluoromethoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(═O)—(ORc)(ORd) group,
or any of its pharmaceutically acceptable salt.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms is a triazole or an oxadiazole.

### Claim 23 (depends on 21)

The method according to claim 21, wherein
ring and
ring both represent a phenylene group or
ring represents a pyridylene group and
ring represents a phenylene group.

### Claim 24 (depends on 21)

The method according to claim 21, wherein
Y1 represents
a 2-pyridinyl group or a 3-pyridinyl group,
a pyrimidinyl group or a pyrazinyl group, with one of the nitrogen atoms being in ortho position with respect to X1,
provided that when X1 is a —NH—CO— group, Y1 may further be a phenyl group, or any of its pharmaceutically acceptable salt.

### Claim 25 (depends on 21)

The method according to claim 21, wherein
X2 represents
a —O— group,
a —CO—NH— group,
a divalent triazole,
or
a —SO2—NH— group,
or any of its pharmaceutically acceptable salt.

### Claim 26 (depends on 21)

The method according to claim 21, wherein
Y2 represents
a hydroxyl group,
a morpholinyl group,
a piperidinyl group, optionally substituted by a (C1-C4)alkyl group,
a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or
a —CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, a fluorine atom or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R and R form together with the carbon atom bearing them a (C3-C8)cycloalkyl group,
or any of its pharmaceutically acceptable salt.

### Claim 27 (depends on 21)

The method according to claim 21, wherein
R and R′ independently represent
a (C1-C4)alkyl group,
a (C3-C6)cycloalkyl group,
a halogen atom, or
a (C1-C5)alkoxy group,
or any of its pharmaceutically acceptable salt.

### Claim 28 (depends on 21)

The method according to claim 21, wherein
ring and
ring both represent a phenylene group,
Y1 represents a 2-pyridinyl group provided that when X1 is a —NH—CO— group,
Y1 may further be a phenyl group,
X2 represents a —O— group, a —CO—NH— group,
Y2 represents
a —CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom, or a (C1-C4)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C8)cycloalkyl group and R3 represents a hydrogen atom or a (C1-C4)alkyl group, or a morpholinyl group, and
R and R′ independently represent a hydrogen atom, (C1-C4)alkyl group, or a (C3-C6)cycloalkyl group, or any of its pharmaceutically acceptable salt.

### Claim 29 (depends on 21)

A method for treating and/or preventing a subject from a RNA vims infection caused by a virus belonging to group IV or V of the Baltimore classification comprising the administration to a patient in need thereof of a therapeutically effective quantity of a compound of formula (Ia)
wherein
Y1, R, R′, m, m′,
ring, X2, n and Y2 are as defined in claim 21,
or any of its pharmaceutically acceptable salt.

### Claim 30 (depends on 29)

The method according to claim 29, wherein
ring is a phenylene group or a pyridylene group,
Y1 represents a 2-pyridyl group, a 3-pyridyl group or a pyrazinyl group,
n is 1, 2 or 3, m is 0,
R′ is a halogen atom, a (C1-C2)alkoxy group or a (C1-C2)alkyl group,
X represents a —CO—NH— group, a —SO2NH— group or a divalent triazole,
Y2 represents
a morpholinyl group, a piperidinyl group or a piperazinyl group, optionally substituted by a (C1-C4)alkyl group,
a —CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R and R form together with the carbon atom bearing them a (C3-C6)cycloalkyl group,
or alternatively X2—Y2 represents a group —C(═O)—NRcRd, wherein Rc and Rd form, together with the nitrogen atom a saturated heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl derivative, or by a trifluoromethyl group,
or any of its pharmaceutically acceptable salt.

### Claim 31 (depends on 21)

A method for treating and/or preventing a subject from a RNA vims infection caused by a virus belonging to group IV or V of the Baltimore classification comprising the administration to a patient in need thereof of a therapeutically effective quantity of compound of formula (Ib)
wherein
Y1, R, R′, m, m′,
ring, X2, n and Y2 are as defined in claim 21,
or any of its pharmaceutically acceptable salt.

### Claim 32 (depends on 31)

The method according to claim 31, wherein
ring is a phenylene group,
Y1 is a phenyl group, a 2-pyridyl group or a pyrimidinyl group with one of the nitrogen atom of the pyrimidinyl group being in the ortho position with respect to the —NH—CO— group,
n is 1, 2 or 3, m is 0, m′ is 0 or 1,
R′ is a (C3-C6)cycloalkyl group,
X2 represents a —CO—NH— group, a —O— group or a divalent triazole,
Y2 represents
a hydroxyl group,
a morpholinyl group, a piperidinyl group or a piperazinyl group, optionally substituted by a (C1-C4)alkyl group,
a —CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group, said (C3-C6)cycloalkyl group being optionally interrupted on said R1 and/or R2 by an oxygen atom,
or any of its pharmaceutically acceptable salt.

### Claim 33 (depends on 31)

A method for treating and/or preventing a subject from a RNA vims infection caused by a virus belonging to group IV or V of the Baltimore classification comprising the administration to a patient in need thereof of a therapeutically effective quantity of compound of formula (Id)
wherein
Y1, R, R′, m, m′,
ring, X2, n and Y2 are as defined in claim 31,
or any of its pharmaceutically acceptable salt.

### Claim 34 (depends on 33)

The method according to claim 33,
wherein
ring is a phenylene group,
Y1 represents a 2-pyridyl group or a 3-pyridyl group,
X represents a —CO—NH— group, a —SO2—NH— group or a divalent triazole,
m′ and m are 0, n is 1, 2 or 3,
Y2 represents a hydroxyl or a —CR1R2R3 group, wherein R1, R2 and R3 independently represent a hydrogen atom or a (C1-C2)alkyl group, being understood that no more than one of R1, R2 and R3 is a hydrogen atom, or R1 and R2 form together with the carbon atom bearing them a (C3-C6)cycloalkyl group,
or any of its pharmaceutically acceptable salt.

### Claim 35 (depends on 21)

The method according to claim 21, wherein the compound of formula (I) is selected from
or any of its pharmaceutically acceptable salt.

### Claim 36 (depends on 21)

The method according to claim 21, wherein the RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification is selected from a RSV viral infection, a Chikungunya viral infection, a Influenza viral infection and a Dengue viral infection.

### Claim 37 (depends on 21)

A compound of formula (I) as defined in claim 21 or any of its pharmaceutically acceptable salt, which is alternatively selected from (1), (2), and (4):
(1) a compound of formula (Ia)
or any of its pharmaceutically acceptable salt,
wherein Y1 is a 2-pyridyl group, 3-pyridyl or a pyrazinyl group,
the group —X2CH2nY2 is in meta position on the
ring, with respect to the —NH— group,
the
ring is a phenylene group, and
with the proviso that compounds 1 and 2 are excluded,
(2) a compound of formula (Ib)
or any of its pharmaceutically acceptable salt,
wherein Y1 is a phenyl group, a 2-pyridyl group or a pyrimidinyl group with one of the nitrogen of the pyrimidinyl group being in the ortho position with respect to the —NH—CO— group,
(4) a compound of formula (Id)
or any of its pharmaceutically acceptable salt,
wherein Y1 is a 2-pyridyl group or a 3-pyridyl group.

### Claim 38 (depends on 35)

A compound according to claim 35 with the exclusion of compounds No 1 and 2, as well as their pharmaceutically acceptable salts.

### Claim 39 (depends on 38)

A compound according to claim 38, wherein the pharmaceutically acceptable salts are selected from hydrobromide, tartrate, citrate, trifluoroacetate, ascorbate, hydrochloride, tosylate, triflate, maleate, mesylate, formate, acetate and fumarate.

### Claim 40 (depends on 38)

A pharmaceutical composition comprising at least one compound as defined in claim 38 or any one of its pharmaceutically acceptable salts, or at least any of compounds (3) to (18), (32) to (35), (91) to (122)
or any of its pharmaceutically acceptable salts and also at least one pharmaceutically acceptable excipient.

### Claim 41 (depends on 37)

Synthesis process for manufacturing compounds of formula (Ia), (Ib), and (Id) as defined in claim 37, comprising at least a step of coupling a compound of formula (II)
with a compound of formula (III)
wherein X1, Y1, R, R′, m, m′,
ring,
ring, X2, Y2 are as defined in claim 37 and X is a chlorine atom, an iodine atom or a bromine atom, in presence of an inorganic base and a diphosphine and in the presence of an organometallic catalyst, to obtain a compound of formula (Ia), (Ib) or (Id) as defined in claim 37.
